Introduction

Clinical manifestations Presentation and course
The onset of idiopathic hypersomnia is often insidious and occurs in the second decade of life with key feature of near constant daytime sleepiness and complaints that the patient almost never feels alert. Along with this background of excessive sleepiness, patients often have long episodes of daytime sleep, with naps lasting over 1 hour. Compared to the daytime sleep episodes that occur in patients with narcolepsy, those associated with idiopathic hypersomnia tend to be more resistible, longer in duration, and not as refreshing. However, this difference from narcolepsy is not absolute and some patients with idiopathic hypersomnia have irresistible daytime sleep episodes and refreshing naps (Aldrich 1996; Bassetti and Aldrich 1997) . The most important clinical distinction is the absence of cataplexy in patients with idiopathic hypersomnia.
Features that distinguished idiopathic hypersomnia from a comparable group of 63 narcoleptics were prolonged and nonrefreshing daytime naps, a positive family history of daytime hypersomnolence, increased slow-wave sleep, and longer sleep latency on the multiple sleep latency test (Anderson et al 2007) . Patients with idiopathic hypersomnia have a reduced quality of life as evidenced by trouble maintaining employment and academic schedules and increased risk for divorce (Ozaki et al 2012) .
Compared with healthy controls (Vernet and Arnulf 2009) , patients with idiopathic hypersomnia have more fatigue, higher anxiety and depression scores, and more frequent hypnagogic hallucinations (24%), sleep paralysis (28%), sleep drunkenness (36%), and unrefreshing naps (46%) than controls. In addition, they depend on others to awaken them, have mental fatigability, and have difficulty maintaining alertness during the day (Vernet et al 2010) .
Prognosis and complications
Idiopathic hypersomnia is usually a chronic, persistent disorder (Bassetti and Aldrich 1997) . In a retrospective chart review only 11% of patients diagnosed with idiopathic hypersomnia were noted to have spontaneous remission of symptoms over the period of observation (Anderson et al 2007) . The complications of idiopathic hypersomnia are mostly related to impairment in daytime functioning due to the excessive sleepiness with significant impact on social, professional, and employment-related activities. The greatest mortality risk with idiopathic hypersomnia remains falling asleep while driving or fatigue-associated driving impairment (Broughton et al 1978; Aldrich 1989 
Clinical vignette
A 23-year-old woman presented with a 2-year history of excessive daytime sleepiness. She reported that she "never" felt refreshed and had significant difficulty awakening from sleep. This caused difficulty with her ability to finish college. Her usual bedtime was 10 PM, and she was awoken by her mother by 7 AM. If not awoken by her parent, she would sleep until 10 AM or longer. She reported having a regular sleep schedule and no difficulty with sleep onset or sleeping through the night. After she was awoken, she reported feeling excessively sleepy, including feeling "sleep drunk," which typically lasted 2 to 3 hours. She denied any nightmares, restless legs symptoms, cataplexy, hypnagogic hallucinations, or sleep paralysis. She drank 6 to 8 double espressos in the morning and coffee throughout the day without a favorable effect. The patient was unable to keep a job due to the sleepiness. She had been exposed to hexane and had developed a neuropathy that had been improving. Her family history was unremarkable, and review of systems was normal.
With a weight of 142 pounds and a height of 5 feet 2 inches, her BMI was calculated to be 26 kg/m 2 . Her vital signs revealed an arterial blood pressure of 113/64 mmHg, temperature of 98.0° F, pulse of 84 beats per minute, respiration
Biological basis Etiology and pathogenesis
The exact cause of idiopathic hypersomnia remains unknown. There are limited data regarding the neurobiology and pathogenesis/pathophysiology of idiopathic hypersomnia, and there is no existing animal model for more detailed study. Many neurochemical studies regarding the disorder have been inconclusive. In a study comparing patients with idiopathic hypersomnia and narcolepsy type 1, using sleep diary and self report measures, 2 subgroups emerged: 1 with family history and 1 with a postinfectious onset (Bruck and Parkes 1996) . These findings suggest the possibility of gene-environment interactions that can contribute to disease in a fashion similar to narcolepsy with hypocretin deficiency.
Neurotransmitters. From a structural perspective, the destruction of noradrenergic neurons of the rostral third of the locus coeruleus complex or of the noradrenergic bundle at the level of the isthmus in the cat leads to hypersomnia with a proportional increase of non-REM sleep and REM sleep, resembling idiopathic hypersomnia (Petitjean and Jouvet 1970) . This state is accompanied by a decrease of diencephalic norepinephrine (Petitjean and Jouvet 1970) . These findings are concordant with the observations of von Economo during the encephalitis lethargica epidemic, which highlighted that patients suffering from excessive sleepiness often had lesions at the junction of the posterior hypothalamus and midbrain (Von Economo 1930) . Additionally, therapeutic measures for idiopathic hypersomnia, such as stimulants and modafinil/armodafinil, which typically act on catecholamine (dopamine, norepinephrine) signaling mechanisms, indicate that there may be some contribution of these neurochemical pathways in the pathogenesis of idiopathic hypersomnia. Other aspects that have been evaluated as possibly contributing to the pathogenesis of idiopathic hypersomnia are histamine signaling, melatonin secretion abnormalities, immunologic and inflammatory processes, somnogens, and genetic factors.
In the 1980s, studies in less well-characterized clinical idiopathic hypersomnia patients found some differences in monoamine metabolites and suggested that idiopathic hypersomnia may have a component of disrupted dopamine signaling. One study found decreased dopamine and indoleacetic acid (tryptophan metabolites) compared to controls in the CSF of patients with narcolepsy and idiopathic hypersomnia (Montplaisir and Poirier 2012) .
Histamine has also been suggested as a biomarker in the pathophysiology of idiopathic hypersomnia, though the evidence is inconclusive (Rye 2012) . Histamine is a wakefulness producing neurotransmitter. In rats, histamine in the frontal cortex is positively correlated with wakefulness (Chu et al 2004) . Additionally, mice that are histamine deficient demonstrate less wakefulness in the early stages of arousal (Parmentier et al 2002) , and H1-deficient mice have fewer arousals from sleep. Anti-histamines (H1 antagonists) are well known to increase somnolence across many species including humans. Two studies evaluated CSF histamine in patients with hypersomnia of various origins. One small, uncontrolled study looked at CSF histamine in patients with multiple causes of excessive daytime sleepiness and found an inverse correlation of CSF histamine with a severity of reported sleepiness based on the Epworth Sleepiness Scale (Bassetti et al 2010) . Kanbayashi and colleagues found that CSF histamine was reduced (compared to controls) in patients with narcolepsy (type 1 and type 2), as well as idiopathic hypersomnia, but not in patients with obstructive sleep apnea (Kanbayashi et al 2009) . However, a larger study looking at histamine, t-methylhistamine, and hypocretin in various conditions that lead to hypersomnia failed to show differences in CSF histamine or t-methylhistamine levels in patients with idiopathic hypersomnia compared to controls (Dauvilliers et al 2012) . From a more clinical perspective, histaminergic compounds like pitolisant, an inverse H3 agonist, have been useful in the management of drug resistant conditions associated with hypersomnia, including idiopathic hypersomnia, through their resultant increases in brain histamine levels (Leu-Semenescu et al 2014).
Investigators have reported on a potential 500-to-3000-dalton somnogen that potentiates γ-hydroxybutyrate (GABA) through activity at the at the benzodiazepine site on the α2 subunit of the GABA A receptor . Blockade of the activity with a benzodiazepine antagonist, flumazenil, has yielded modest results in a small proportion of a cohort of mixed hypersomnia patients (Trotti et al 2016) .
Although hypocretin-1 is implicated in narcolepsy type 1, this neurotransmitter does not appear to be pathogenic in idiopathic hypersomnia (Dauvilliers et al 2012) .
Inflammatory/cytokines. Some studies indicate that idiopathic hypersomnia may have an immunological or inflammatory component, similar to narcolepsy type 1. Among patients with idiopathic hypersomnia, human leukocyte antigen-Cw2 was found in 22.2% compared to 5.7% in controls (p < 0.05) (Montplaisir and Poirier 2012) . Also, HLA-DR5, which is in linkage dysequilibrium with HLA-Cw2, was present in 38.8% of patients versus 14.6% of controls (Montplaisir and Poirier 2012) . Further studies, however, did not find any similar association with idiopathic hypersomnia and HLA haplotypes (Bassetti and Aldrich 1997; Billiard et al 1998) . However, the poor associations with HLA regions may be explained by the variability of subjects exposed to a triggering factor (eg, infection, as in narcolepsy type 1) (Longstreth et al 2009; Dauvilliers et al 2010) , as well as the fact that idiopathic hypersomnia represents a heterogenous population. Nonetheless, additional data that indicate there may be an immunological component are the serum total IgG levels in 28 Japanese patients with idiopathic hypersomnia and long sleep times.
Those patients with idiopathic hypersomnia had high IgG3 and IgG4 levels, low IgG2 level, and IgG1/IgG2 imbalance, which was different than healthy individuals (Tanaka and Honda 2010) .
Related to the immune-mediated-disease hypothesis is the observation that proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFα) are elevated in disorders associated with excessive daytime sleepiness, such as sleep apnea, narcolepsy, and idiopathic hypersomnia. Although these cytokines are part of the innate immune system, their activity meets the criteria of a somnogen/sleep regulatory substance (Krueger et al 2015) . Most notably, sleep deprivation also leads to sleepiness and daytime hypersecretion of IL-6. These findings suggest that IL-6 and TNFα are possible mediators of excessive daytime sleepiness in humans (Vgontzas and Chrousos 2002) .
Genetics. A genetic basis for some cases of idiopathic hypersomnia is suggested by several investigations. Early studies indicated that a large minority of patients with idiopathic hypersomnia had a similarly affected first degree relative (Nevsimalova-Bruhova and Roth 1972; Roth and Broughton 1980; Billiard and Besset 1998) . Although these data strongly suggest a genetic component, possibly autosomal dominant, the limited number of families studied has not permitted definitive determination of the mode of inheritance. A number of studies have sought to explore the genetic basis of sleep duration using genome-wide association studies. Unfortunately, sample size limitations and phenotype heterogeneity have limited the findings thus far. To date, the largest analysis of genetic contributions to sleep duration has come from a study of individuals in the UK Biobank (http://www.ukbiobank.ac.uk) (Jones et al 2016) .
The findings confirmed a prior association (Gottlieb et al 2015) with the thyroid-specific transcription factor, PAX8, and identified a novel association with a multicascade serine/threonine kinase, VRK2 (Allebrandt et al 2013) . However, the variants associated with the identified genes conferred insubstantial effects on sleep duration (2.6 min per PAX8 allele and 1.6-2.0 min per VRK2 associated variant), highlighting the difficulties in identifying the genetic contributors to such multifactorial phenotypes. Future study of extreme, well-phenotyped individuals and multiplex families may reveal more meaningful associations.
Additionally, circadian rhythm gene-expression analyses have revealed some abnormalities in individuals with idiopathic hypersomnia; however, causality has yet to be established. In 2014, a study by Lippert and colleagues evaluated gene expression of certain circadian clock genes in cultured dermal fibroblasts of patients with a diagnosis of idiopathic hypersomnia compared to that in normal healthy controls (Lippert et al 2014) . This study revealed statistically significant reductions in the amplitude of the expected oscillation in the transcription of BMAL1, PER1, and PER2 (Lippert et al 2014) . The authors postulated that the dampening of oscillations of these transcriptional factors in the SCN, which modulate pineal melatonin secretion, may explain the decreased melatonin secretion seen in idiopathic hypersomnia (Teclemariam-Mesbah et al 1999; Nevsimalova et al 2000) .
In sum, despite a number of intriguing findings spanning the domains of CNS neurotransmitters, immunology, and genetics, the pathophysiology underlying idiopathic hypersomnia remains nebulous. A number of factors contribute to this elusive disorder, not the least of which include the poor objective characterization of this phenotype with the currently available diagnostic methods (see management section below), the genetic complexity, the unclear risk factors, and environmental exposures.
Epidemiology"
Evaluation of the prevalence of idiopathic hypersomnia in the general population is difficult due to the limited number of patients with this condition and the difficulty of making a definitive diagnosis. For example, after excluding patients with symptoms and medication that might confound a diagnosis in patients with daytime sleepiness, Laffont and colleagues comprehensively evaluated 128 patients (16 to 77 years of age) in whom no clear diagnosis had been established for their daytime sleepiness and found that only 12% (15 patients) fit criteria for idiopathic hypersomnia.
Using their own nomenclature they characterized the other subjects as having various disorders such as: mild hypersomnia type 1, hypersomnia associated with HLA type DR2-DQw1, mild hypersomnia type 2, patients with morning recovery from disrupted sleep, young "long sleepers" with difficulty waking up, poor short sleepers since childhood, and older poor sleepers with late onset of symptoms (Laffont et al 2002) .
Despite the limited nature of epidemiological data, the prevalence of idiopathic hypersomnia patients compared to narcoleptic patients provides some indication of overall prevalence. For comparison, improvements in recognition and diagnosis of type 1 narcolepsy have pointed to an estimated prevalence of 0.02% to 0.03% (Mignot 1998) . Based on review of a large cohort of over 6000 patients with sleep disorders in the United Kingdom, idiopathic hypersomnia was found to be 40% to 60% as prevalent as narcolepsy, depending upon what MSLT criteria is used (Anderson et al 2007) .
These findings are lower than those in earlier studies, probably because of improved identification of sleep disorders that were formerly diagnosed as idiopathic hypersomnia. Integrating these findings into a metaanalysis exploring the epidemiology, diagnosis, pathophysiology, and treatment of idiopathic hypersomnia suggested that the prevalence of idiopathic hypersomnia in the adult population is between 1 in 5000 and 1 in 50,000.
Clinically, approximately 10% to 29% of individuals referred to a sleep center for excessive daytime sleepiness ultimately receiving a diagnosis of idiopathic hypersomnia (Sowa 2016; Saini and Rye 2017) .
Prevention
Prevention and risk factors are unknown.
Differential diagnosis
Idiopathic hypersomnia is probably 1 of the most frequently misdiagnosed sleep disorders, potentially due to disorders that are less recognized than narcolepsy and obstructive sleep apnea, yet can cause excessive daytime sleepiness.
Many other conditions produce such sleepiness and can mimic or coexist with a hypersomnia of central origin. All of these possible confounders need to be considered in the differential diagnosis as possibly causing or contributing to the excessive sleepiness in a patient with hypersomnia of central origin (Morgenthaler et al 2007) .
An exploration of the causes of excessive daytime sleepiness (EDS) in 16,583 randomly sampled Pennsylvanians identified 1742 sleepy individuals who were then recruited for laboratory evaluation. Regression analysis revealed that a report of being treated for depression is the most significant risk factor for the complaint of excessive daytime sleepiness (with increasing effects in younger individuals), followed by BMI, age, subjective estimate of typical sleep duration, diabetes, smoking, and finally sleep apnea (Bixler et al 2005) . This emphasizes that potentially confounding medical/psychiatric disorders and their treatments (Pagel 2009; Gonçalves and Togeiro 2013) Excessive sleepiness may be the first symptom of progressive hydrocephalus in the absence of other features of hydrocephalus. Systemic exertional intolerance disease (formerly known as chronic fatigue syndrome, or myalgic encephalomyelitis, despite a lack of evidence of CNS inflammation) is characterized by persistent or relapsing fatigue that does not resolve with bedrest. It is important to differentiate sleepiness (a propensity for dozing off) from fatigue (a lack of physical energy, or body "tiredness"), in any such patients (Krupp et al 1989) . Additionally, there are a number of genetic syndromes that result in hypersomnia including autosomal dominant cerebellar ataxia, deafness, Hypersomnia due to medication or substance is based on excessive daytime sleepiness and an irresistible urge to sleep due to substance/sedative use or withdrawal from stimulant medications. Substances or sedating medications can include alcohol, opiates, marijuana, benzodiazepines, non-benzodiazepine hypnotics, barbiturates, anti-epileptic medications, antipsychotic medications, anticholinergics, antihistamines, antidepressants, and/or combination of medications. Beyond the obvious psychotropic sedatives, a plethora of medications have drowsiness listed as a side effect, either through primary or off-target effects (Gonçalves and Togeiro 2013) . Withdrawal from or abrupt cessation of stimulants such as amphetamines or caffeine can also lead to symptoms of hypersomnia. This can be distinguished from idiopathic hypersomnia with a careful and detailed history, and polysomnography is generally unnecessary.
Hypersomnia associated with psychiatric disorders (dysthymia and related mood disorders) can be distinguished from idiopathic hypersomnia based upon its onset later in life and findings of low-grade, chronic depression revealed through clinical interviews and psychometric testing. In fact, as noted above, depression conferred the highest risk of excessive daytime sleepiness (OR 6.85, p < 0.001) in a large multiple logistic regression model (Bixler et al 2005) . The multiple sleep latency test often does not demonstrate a short mean sleep latency in depression associated hypersomnia, and continuous 24-hour polysomnography shows normal daytime wakefulness despite patients having relative motor quiescence. Thus, they may not move but they are awake (Dolenc et al 1996) . Treatment of hypersomnia may or may not improve depression scores, indicating that the relationship between mood disorders and hypersomnia is more complex than simple cause and effect (Haba-Rubio 2005) , particularly in light of the fact that idiopathic hypersomnia patients will develop depression as a result of diagnostic delays and the psychosocial burden of their disease (Dauvilliers et al 2009; Vernet et al 2010) . Thus, a concerted approach focused on treating both disorders is essential.
After addressing the primary medical and psychiatric conditions that may result in sleepiness, the most obvious disorders that contribute to excessive daytime sleepiness are the sleep disorders that impair sleep quality and quantity: sleep-disordered breathing (eg, obstructive sleep apnea), restless legs syndrome, periodic limb movement disorder, and circadian phase disorders (Slater and Steier 2012) . A less-commonly-known sleep breathing disorder is the upper airway resistance syndrome (UARS). Subjects with UARS may complain of excessive daytime sleepiness (Guilleminault et al 1993) . Polysomnography discloses short alpha EEG arousals lasting 3 to 14 seconds that regularly interrupt snoring periods, which are polysomnographically scored as respiratory-event-related arousals (RERA). UARS is classified within obstructive sleep apnea by the American Academy of Sleep Medicine based on the most recent edition of the International Classification of Sleep Disorders (ICSD) (American Academy of Sleep Medicine 2014). To make this diagnosis in adults, the calculated respiratory disturbance index (RDI) should be greater than 5 events per hour (with AHI less than 5 per hour) (Guilleminault and Los Reyes 2011) . Furthermore, circadian misalignment (most commonly problematic in those with delayed sleep phase syndrome) is a diagnostic consideration in patients whose main complaint is extreme difficulty awakening at the desired time and excessive morning sleepiness. However, these patients are not sleepy in the evening and go to bed extremely late in the night (Weitzman et al 1981) . The diagnosis can be confirmed with review of sleep diary and actigraphy.
Consideration of other primary CNS hypersomnias must also be given. In particular, type 1 narcolepsy is often differentiated through the presence of the telltale presence of cataplexy, which is a sudden loss of muscle tone in response to (usually positive) emotion (Scammell 2015) . Differentiation of idiopathic hypersomnia from the nonhypocretin-deficient, type 2 narcolepsy is far more challenging, and clinical symptoms alone cannot provide a clear differentiation of the disorders (Sonka et al 2015) , as they are nonspecific to any of the primary hypersomnias (Saini and Rye 2017) . Kleine-Levin syndrome is a rare disorder characterized by recurrent episodes of excessive sleepiness (episodes typically lasting 10 days, but possibly up to a few weeks) associated with cognitive dysfunction, altered perception of the environment, eating disorder (commonly hyperphagia), and/or disinhibited behavior (such as hypersexuality), with onset usually in adolescence, and gradual remission often over many years. Most remarkable is that these patients appear to return to a completely normal baseline in the months between the episodes of hypersomnia, and may suffer from a degree of amnesia or report derealization of the event (American Academy of Sleep Medicine 2014).
Given the current epidemic of sleep deprivation (Centers for Disease Control and Prevention 2015), behaviorallyinduced insufficient sleep syndrome must be considered in all individuals presenting with excessive daytime sleepiness, impaired concentration, and lowered energy level. A detailed history of the current sleep schedule is revealing, and actigraphy can also be useful in establishing a wake-sleep pattern (Roehrs et al 1983) .
Finally, normal variations in the amount of sleep needed per night can include adults who require longer sleep times, greater than 10 hours (in 24 hour period). They may be misdiagnosed with idiopathic hypersomnia because of extremely long sleep episodes at night. However, these patients are normally alert once they have slept their needed amount of sleep.
Diagnostic workup
The diagnosis of idiopathic hypersomnia is mainly based upon findings discovered during a clinical history. However, actigraphy, polysomnography, and multiple sleep latency testing (MSLT) are necessary to confirm the diagnosis and to rule out other sleep disorders. The most widely used test is overnight polysomnography, followed by the MSLT. This sequence of sleep studies allows sleep-disordered breathing, narcolepsy, periodic leg movements, and sleep fragmentation to be ruled out as causes of excessive daytime sleepiness.
One of the most common mistakes made performing the PSG-MSLT is to wake the patient up in the morning instead of letting them sleep in as long as they can. This leads an individual who may have a prolonged sleep requirement or a circadian rhythm delay to have shortened sleep latencies and risk a false positive result.
The MSLT was originally devised for the diagnosis of narcolepsy type 1 (Carskadon and Dement 1994) , where it is best validated (Folkerts et al 1996) . However, outside of narcolepsy type 1, its diagnostic utility is more limited (Mignot et al 2006; Trotti et al 2013) . A mean sleep latency cutoff of 8 minutes (less than 8 minutes suggestive of hypersomnia) has poor reliability, as many idiopathic hypersomnia patients have mean sleep latencies of more than 8 minutes (leading to a false negative result) and 22% of the general public have sleep latencies of less than 8 minutes (leading to a false positive result) (Carskadon et al 1986 HLA typing is not sufficiently specific or sensitive to use for diagnosis of idiopathic hypersomnia. The HLA-DQB1*06:02 allele is highly prevalent (97%) in narcolepsy type 1, but is also found frequently ( Management Treatment of idiopathic hypersomnia is similar to that of narcolepsy, however, with substantially less evidence to support the various therapies. Further, as there are no FDA-approved treatments for idiopathic hypersomnia, medications are used off-label and, thus, must be used cautiously with clearly expressed and documented patient understanding of the risks and benefits of such usage. Nonmedication treatment can include lifestyle modification, attention to sleep hygiene, and/or scheduled naps (Adenuga and Attarian 2014) . Education about the impact of the condition on academic development, work, driving, and social life can assist patients as they attempt to live a normal life.
Modafinil and armodafinil (the R racemate of modafinil) have a benefit/risk profile in idiopathic hypersomnia similar to its effect on narcolepsy type 1 (Bastuji and Jouvet 1988; Lavault et al 2011) . Modafinil has been reported to have a modest but significant effect on hypersomnia in children (Ivanenko et al 2003; Anderson et al 2007) . With response rates as high as 72% (after accounting for dropouts due to factors such as cost) (Ali et al 2009) , the American Academy of Sleep Medicine has concluded that modafinil might be an effective therapy for idiopathic hypersomnia (Morgenthaler et al 2007) .
Other psychostimulant drugs such as dextroamphetamine and methylphenidate are the mainstays of treatment, however, due to their high potential for abuse and undesirable side-effects these medications are often reserved for second-line therapy, with a preference for long-acting agents (Morgenthaler et al 2007) . For reasons unclear, these medications do not often result in sustained benefits for idiopathic hypersomnia as they do in narcolepsy. This may result in attempts to achieve better clinical response by exceeding recommended maximum guideline dosages.
Exceeding standard dosages often precipitates psychosis, headache, substance misuse, tachyarrhythmia, anorexia, or other significant side effects (Auger et al 2005) .
Additional therapies have been employed in treatment-refractory idiopathic hypersomnia patients. Sodium oxybate, an agonist at the γ-hydroxybutyrate and GABA B receptors that promotes slow-wave sleep, was studied in 46 idiopathic hypersomnia patients, revealing a good response in 65% of the 39 patients that chose to fill the prescription (LeuSemenescu et al 2016). The antibiotic clarithromycin may be a negative allosteric inhibitor of the GABA A receptor, which prompted study of its effects in a retrospective chart review and small clinical trial, both of which showed modest benefits (Trotti et al 2014; Trotti et al 2015) . Similarly the benzodiazepine receptor agonist, flumazenil, was studied by the same group, with minor benefits in psychomotor vigilance task measures and subjective alertness . An inverse agonist targeting the autoinhibitory H3 histamine receptor, pitolisant, has been studied in idiopathic hypersomnia and narcolepsy with clinically significant improvements in excessive daytime sleepiness (LeuSemenescu et al 2014; Szakacs et al 2017) . Finally, a trial of transcranial direct current stimulation demonstrated an improvement in sleepiness and attention compared to baseline evaluation (Galbiati et al 2016) . Hopefully further investigations of these and other therapies will result in the discovery of therapies with sustained efficacy for idiopathic hypersomnia. Complications of treatment are medication-specific. In general, the psychostimulants used to treat idiopathic hypersomnia result in side effects through their action on the monoaminergic neurotransmitter systems. Medications that work primarily through reuptake inhibition (eg, modafinil) are generally better tolerated than those that also result in dopamine release or norepinephrine reuptake inhibition at higher doses (eg, amphetamine salts). Postmarketing monitoring revealed a risk for Stevens-Johnson syndrome in modafinil (Cephalon Inc. 2007b) , and there is diminished hormonal contraceptive efficacy while taking this medication class (Cephalon Inc. 2007a; Cephalon Inc. 2007b ). The traditional psychostimulants (eg, amphetamine salts and methylphenidate) are more sympathomimetic, resulting in a higher risk of toxicity, in addition to the higher risk of abuse (Stiefel and Besag 2010; Leviel 2011; Mignot 2012) .
Outcomes
Sodium oxybate has a heightened risk of anxiety and depression with suicidal ideation. In addition it carries a high sodium load, suggesting a need for caution in patients with heart failure or renal insufficiency (Jazz Pharmaceuticals 2002; Ortega-Albás et al 2010; Rossetti et al 2010) .
Special considerations Pregnancy
No data are available on the effect of pregnancy on idiopathic hypersomnia or of idiopathic hypersomnia on pregnancy. Attention to FDA pregnancy categories for medications used for treatment is essential as most medications are category C (ie, amphetamines, methylphenidate, modafinil, and armodafinil).
Anesthesia
In patients with idiopathic hypersomnia, stimulant drugs should be discontinued in anticipation of surgery. The effects of anesthesia on idiopathic hypersomnia are unknown. 
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